Abstract
Aim. To assess the microalbuminuria (MAU) and vascular wall elasticity in patients with essential hypertension (HT) and evaluate the possibilities to reduce in fatal cardiovascular risk due to lisinopril (Listril, Dr Reddy’s) therapy. Material and methods. 42 patients (60,3±0,83 y.o.) with HT were involved in the study. Pulse wave velocity was estimated by volume sphygmography. MAU levels were detected with micral-test (Roche Diagnostics, Germany). Patients received lisinopril as a first-step antihypertensive drug, if necessary the dose of lisinopril was increased or amlodipine was added. The treatment lasted for 12 weeks. Results. MAU was revealed more often in patients with increased body mass index as compared with whole population of hypertensive patients. MAU was associated with increased vascular wall stiffness. Lisinopril therapy during 4 weeks allowed to reach target level of blood pressure (BP) in 42,9% of patients and decreased in MAU level by 54,5%. Therapy continuation during 12 weeks allowed to reach target level of BP in 90,4% of patients and reduce in fatal cardiovascular risk by 36,6%. Conclusion. Lisinopril therapy resulted in significant reduction in BP, MAU and fatal cardiovascular risk in patients with HT.
Highlights
To assess the microalbuminuria (MAU) and vascular wall elasticity in patients with essential hypertension (HT) and evaluate the possibilities to reduce in fatal cardiovascular risk due to lisinopril (Listril, Dr Reddy’s) therapy
Lisinopril therapy resulted in significant reduction in blood pressure (BP), MAU and fatal cardiovascular risk in patients with HT
3. Гипотензивная терапия в течение 12 недель (основной первый препарат – Листрил) позволила достичь целевых значений артериального давления (АД) у 90,4% пациентов и снизить риск фатального сосудистых заболеваниях (ССЗ) на 36,6%
Summary
Микроальбуминурия как фактор прогноза сердечно-сосудистых осложнений и маркер эффективности терапии у пациентов с артериальной гипертонией Л.А. Оценить микроальбуминурию (МАУ) и эластичность сосудистой стенки у пациентов с эссенциальной артериальной гипертонией (АГ) и возможности снижения у них фатального сердечно-сосудистого риска благодаря приему ингибитора АПФ лизиноприла (Листрил, Dr Reddy’s). Aim. To assess the microalbuminuria (MAU) and vascular wall elasticity in patients with essential hypertension (HT) and evaluate the possibilities to reduce in fatal cardiovascular risk due to lisinopril (Listril, Dr Reddy’s) therapy. Lisinopril therapy resulted in significant reduction in BP, MAU and fatal cardiovascular risk in patients with HT. В настоящее время МАУ рассматривается как важный самостоятельный признак повышенного риска развития сердечно-сосудистых осложнений и смерти больных АГ, сахарным диабетом и в общей популяции, отражающий системную сосудистую дисфункцию [8]. Цель исследования – выявление микроальбуминурии, изучение особенностей сосудистой стенки и оценка возможности снижения фатального сердечно-сосудистого риска на фоне приема Листрила (лизиноприл, Dr Reddy’s) у больных эссенциальной АГ
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
